Usage, dosage, and special population use of Amivantamab from Janssen Pharmaceuticals in the United States
The usage and dosage of Amivantamab should be adjusted according to the indications, and factors such as pregnancy, liver and kidney function should be considered when using it for special populations. The following will explain from two aspects: standard dosage regimen and precautions for special populations.
1. Standard usage and dosage
(1) Basic dose for non-small cell lung cancer
The first dose is calculated based on body weight: 1050mg for patients weighing less than 80kg, 1400mg for patients weighing ≥ 80kg, and intravenous infusion for ≥ 3 hours. Maintain the same dosage once a week thereafter.
(2) Pre treatment before infusion
Antihistamines and acetaminophen should be used to prevent reactions before the first infusion. The pre-treatment plan for subsequent infusion should be adjusted according to tolerance.
(3) Principle of dose adjustment
If a grade ≥ 3 adverse reaction occurs, the medication should be suspended and resumed at 75% of the original dose after recovery. Specific immune related toxicity requires permanent discontinuation of medication.
2. Medication for special populations
(1) Pregnant women
Animal studies have shown embryotoxicity, and pregnant women should avoid using it. Before treatment, it is necessary to confirm the pregnancy status and use contraception during the medication period and within 3 months after the last dose.
(2) Lactating women
Medication may be secreted into breast milk. Breastfeeding is prohibited during treatment and for one month after discontinuation of medication. The necessity of breastfeeding needs to be evaluated.
(3) Liver dysfunction
Mild to moderate damage does not require dose adjustment, and severe liver dysfunction (Child Pugh C grade) lacks data and should be used with caution.
(4) Renal insufficiency
Mild to moderate damage does not require adjustment, severe (eGFR<30mL/min) or insufficient data for dialysis patients, close monitoring is recommended.
(5) Elderly patients
Patients over 65 years old do not need to adjust the dosage, but it is necessary to strengthen adverse reaction monitoring as complications may increase the risk of toxicity.
(6) Pediatric patients
The safety and efficacy of using it for patients under 18 years old have not been established and is not recommended. Alternative treatment options need to be considered.
Disclaimer：《Usage, dosage, and special population use of Amivantamab from Janssen Pharmaceuticals in the United States》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！